Egalet acquires pain products Oxaydo and Sprix

WAYNE, Penn. — Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated. The drug is approved in the United States for the management of acute and chronic moderate to severe pain. 

 

Additionally, Egalet acquired Sprix (ketorolac tromethamine) nasal spray from Luitpold Pharmaceuticals. The spray is a non-steroidal anti-inflammatory drug used as a short-term treatment for moderate to moderately severe pain that requires anaglesia at the opioid level. 

 

“The license and acquisition of Oxaydo and Sprix, two approved innovative pain treatments, helps transform Egalet into a fully integrated specialty pharmaceutical company in advance of the approval of our highly differentiated, late-stage pipeline of abuse-deterrent, extended-release products,” said Bob Radie, president and CEO of Egalet. “These products, an immediate-release opioid formulated to deter abuse and a nasal spray NSAID delivering pain relief at an opioid level, are natural fits given our focus on providing patients treatment options for pain that may help deter abuse and misuse, as well as accelerate our path to revenue generation and profitability.”

 

Egalet will assume responsibility of Sprix and begin promotional efforts in the first quarter of 2015, the company stated. Egalet is set to launch Oxaydo in the third quarter of 2015.